The endocannabinoid anandamide inhibits cholangiocarcinoma growth via activation of the noncanonical Wnt signaling pathway
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Cholangiocarcinomas are cancers that have poor prognosis and limited treatment options. The noncanonical Wnt pathway is mediated predominantly by Wnt 5a, which activates a Ca 2+-dependent pathway involving protein kinase C, or a Ca 2+-independent pathway involving the orphan receptor Ror2 and subsequent activation of Jun NH 2-terminal kinase (JNK). This pathway is associated with growth-suppressing effects in numerous cell types. We have shown that anandamide decreases cholangiocarcinoma growth in vitro. Therefore, we determined the effects of anandamide on cholangiocarcinoma tumor growth in vivo using a xenograft model and evaluated the effects of anandamide on the noncanonical Wnt signaling pathways. Chronic administration of anandamide decreased tumor growth and was associated with increased Wnt 5a expression in vitro and in vivo. Treatment of cholangiocarcinoma cells with recombinant Wnt 5a decreased cell proliferation in vitro. Neither anandamide nor Wnt 5a affected intracellular calcium release, but both increased the JNK phosphorylation. Stable knockdown of Wnt 5a or Ror2 expression in cholangiocarcinoma cells abolished the effects of anandamide on cell proliferation and JNK activation. Modulation of the endocannabinoid system may be important in cholangiocarcinoma treatment. The antiproliferative actions of the noncanonical Wnt signaling pathway warrants further investigation to dissect the mechanism by which this may occur.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653 · cited 1×
“These factors are necessary for the vascularization of the tumors (13, 14) and contribute to the development and growth of cholangiocarcinoma tumors.”
BackgroundThe endocannabinoid system as a target for therapeutic drugs
Piomelli, D., Giuffrida, A., Calignano, A., & Rodrı́guez de Fonseca, F. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01482-6 · Cited by 421 · cited 1×
“Ongoing research is determining that regulation of the endocannabinoid system may be effective in the treatment of pain (6, 29), glaucoma (48), and neurodegenerative disorders such as Parkinson’s disease (33) and multiple sclerosis (3).”
BackgroundModulation of Embryonic Intracellular Ca2+Signaling byWnt-5A
Slusarski, D. C., Yang-Snyder, J., Busa, W. B., & Moon, R. T. (1997) · Developmental Biology · doi:10.1006/dbio.1996.8463 · Cited by 404 · cited 1×
“Activation of this pathway is thought to trigger the intracytoplasmic release of Ca(2) and the activation of subsequent Ca(2) -related signaling (41).”
BackgroundWnt-5A/Ror2 Regulate Expression of XPAPC through an Alternative Noncanonical Signaling Pathway
Schambony, A., & Wedlich, D. (2007) · Developmental Cell · doi:10.1016/j.devcel.2007.02.016 · Cited by 310
Cited by
Banales, J. M., Cardinale, V., Carpino, G., Marzioni, M., Andersen, J. B., Invernizzi, P., Lind, G. E., Folseraas, T., Forbes, S. J., Fouassier, L., et al. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.51 · Cited by 1,376
Self-citationFraguas-Sánchez, A. I., & Torres-Suárez, A. I. (2018) · Drugs · doi:10.1007/s40265-018-0996-1 · Cited by 271
Quinn, M., McMillin, M., Galindo, C., Frampton, G., Pae, H. Y., & DeMorrow, S. (2014) · Digestive and Liver Disease · doi:10.1016/j.dld.2014.01.159 · Cited by 259
Suppression of the HPA axis during cholestasis can be attributed to hypothalamic bile acid signaling
McMillin, M., Frampton, G., Quinn, M., Divan, A., Grant, S., Patel, N., Newell-Rogers, K., & DeMorrow, S. (2015) · Molecular Endocrinology · doi:10.1210/me.2015-1087 · Cited by 82
“To suppress ASBT expression in hypothalamic neurons, MhypoA-21 cells were transfected with an ASBT shRNA expression vector (Mhypo-ASBT shRNA) conferring resistance to puromycin following the methodology described previously (34).”
MethodSelf-citationMcMillin, M., Grant, S., Frampton, G., Petrescu, A. D., Williams, E., Jefferson, B., Thomas, A., Brahmaroutu, A., & DeMorrow, S. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1455-y · Cited by 29
Self-citation
Metadata
- Authors
- DeMorrow, S., Francis, H., Gaudio, E., Venter, J., Franchitto, A., Kopriva, S., Onori, P., Mancinelli, R., Frampton, G., Coufal, M., Mitchell, B., Vaculin, B., & Alpini, G.
- Venue
- American Journal of Physiology-Gastrointestinal and Liver Physiology
- Publisher
- American Physiological Society
- Published
- 2008-12
- Volume
- 295
- Issue
- 6
- Pages
- G1150-G1158
- ISSN
- 0193-1857 (ISSN-L)
- 1522-1547
- OpenAlex
- W2080537530
- Cited by
- 72
- References
- 4
- FWCI
- 5.17
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The endocannabinoid anandamide inhibits cholangiocarcinoma growth via activation of the noncanonical Wnt signaling pathway. https://app.cochat.ai/papers/10.1152/ajpgi.90455.2008
- The paper
- DeMorrow, S., Francis, H., Gaudio, E., Venter, J., Franchitto, A., Kopriva, S., Onori, P., Mancinelli, R., Frampton, G., Coufal, M., Mitchell, B., Vaculin, B., & Alpini, G. (2008). The endocannabinoid anandamide inhibits cholangiocarcinoma growth via activation of the noncanonical Wnt signaling pathway. American Journal of Physiology-Gastrointestinal and Liver Physiology. https://doi.org/10.1152/ajpgi.90455.2008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.